Stribild Tablets Dosage

Generic name: elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
Dosage form: tablet, film coated

This dosage information does not include all the information needed to use Stribild Tablets safely and effectively. See full prescribing information for Stribild Tablets.

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

The recommended dose of STRIBILD is one tablet taken orally once daily with food [See Clinical Pharmacology (12.3)].

Renal Impairment: STRIBILD should not be initiated in patients with estimated creatinine clearance below 70 mL per min. Because STRIBILD is a fixed-dose combination tablet, STRIBILD should be discontinued if estimated creatinine clearance declines below 50 mL per min during treatment with STRIBILD as dose interval adjustment required for emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) cannot be achieved [See Warnings and Precautions (5.3), Adverse Reactions (6.1), Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Clinical Studies (14)].

Hepatic Impairment: No dose adjustment of STRIBILD is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. No pharmacokinetic or safety data are available regarding the use of STRIBILD in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, STRIBILD is not recommended for use in patients with severe hepatic impairment [See Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

More about Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)

Consumer resources

Professional resources

Compare with other treatments for: